Compare JAGX & XAIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JAGX | XAIR |
|---|---|---|
| Founded | 2013 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.9M | 4.3M |
| IPO Year | 2014 | 2015 |
| Metric | JAGX | XAIR |
|---|---|---|
| Price | $0.87 | $6.32 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $60.00 | $10.00 |
| AVG Volume (30 Days) | ★ 104.5K | 39.3K |
| Earning Date | 04-07-2026 | 06-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 82.42 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $11,511,000.00 | $7,679,000.00 |
| Revenue This Year | $61.58 | $122.00 |
| Revenue Next Year | N/A | $58.15 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 107.26 |
| 52 Week Low | $0.22 | $0.33 |
| 52 Week High | $8.00 | $8.19 |
| Indicator | JAGX | XAIR |
|---|---|---|
| Relative Strength Index (RSI) | 24.13 | 62.82 |
| Support Level | $0.60 | $0.64 |
| Resistance Level | $0.99 | $7.96 |
| Average True Range (ATR) | 0.09 | 0.73 |
| MACD | 0.03 | -0.09 |
| Stochastic Oscillator | 9.01 | 47.44 |
Jaguar Health Inc is a commercial-stage pharmaceutical company developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for gastrointestinal disease states in humans and animals. The Company focuses on conditions associated with overactive bowel, including chronic debilitating diarrhea, urgency, and bowel incontinence. It operates through two segments: animal health, which develops and commercializes products for animals, and human health, with the human health segment generating the maximum revenue and focusing on products such as Mytesi, focusing on human products, specifically Mytesi, approved for symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.
Beyond Air Inc a commercial-stage medical device and biopharmaceutical company developing a platform of nitric oxide (NO) generators and delivery systems (the LungFit platform) capable of generating NO from ambient air. Its segments are Beyond Air, Beyond Cancer, and NeuroNos. The company generates majority of revenue from Beyond Air. It has developed the Beyond Air NO generator and delivery system which it call LungFit, a novel and precise delivery system that uses NO generated from ambient air with a novel NO generator, the ionizer. Its product and technology includes LungFitPH.